Cargando…

Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017

BACKGROUND: Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients on opioid agonist therapy (OAT) are common and have pros and cons. The objectives of the current study are to define the dispensation rates of these potentially addictive drugs, and whether the number and the m...

Descripción completa

Detalles Bibliográficos
Autores principales: Vold, Jørn Henrik, Skurtveit, Svetlana, Aas, Christer, Chalabianloo, Fatemeh, Kloster, Pia Synnøve, Johansson, Kjell Arne, Fadnes, Lars Thore
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183604/
https://www.ncbi.nlm.nih.gov/pubmed/32334602
http://dx.doi.org/10.1186/s12913-020-05195-5
_version_ 1783526451919716352
author Vold, Jørn Henrik
Skurtveit, Svetlana
Aas, Christer
Chalabianloo, Fatemeh
Kloster, Pia Synnøve
Johansson, Kjell Arne
Fadnes, Lars Thore
author_facet Vold, Jørn Henrik
Skurtveit, Svetlana
Aas, Christer
Chalabianloo, Fatemeh
Kloster, Pia Synnøve
Johansson, Kjell Arne
Fadnes, Lars Thore
author_sort Vold, Jørn Henrik
collection PubMed
description BACKGROUND: Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients on opioid agonist therapy (OAT) are common and have pros and cons. The objectives of the current study are to define the dispensation rates of these potentially addictive drugs, and whether the number and the mean daily doses of dispensed OAT opioids and discontinuing OAT, are associated with being dispensed benzodiazepines, z-hypnotics and gabapentinoids among patients on OAT in Norway in the period 2013 to 2017. METHODS: Information about all dispensed opioids, benzodiazepines, z-hypnotics and gabapentinoids were recorded from the Norwegian Prescription Database (NorPD). A total of 10,371 OAT patients were included in the study period. The dispensation rates were defined as the number of patients who were dispensed at least one of the potentially addictive drugs divided among the number of patients who have dispensed an OAT opioid per calendar year. Mean daily doses were calculated, and for benzodiazepines and z-hypnotics, stated in diazepam equivalents. The association between dispensed potentially addictive drugs, and the number and the type of dispensed OAT opioids were calculated by using logistic regression models. RESULTS: Half of the OAT patients received at least one dispensation of a benzodiazepine or z-hypnotic, and 11% were dispensed at least a gabapentinoid in 2017. For dispensed benzodiazepines or z-hypnotics, the mean daily dose was reduced from 21 mg (95% confidence interval (CI): 20–23) diazepam equivalents in 2013 to 17 mg (95% CI: 16–17) in 2017. The mean daily dose of pregabalin increased from 365 mg (95% CI: 309–421) in 2013 to 386 mg (95% CI: 349–423) in 2017. Being dispensed a gabapentinoid (adjusted odds ratio (aOR) = 2.5, 95% CI: 2.1–3.0) or a non-OAT opioid (aOR = 3.0, 95% CI: 2.6–3.5) was associated with being dispensed a benzodiazepine or z-hypnotic. Discontinuing OAT did not affect the number of dispensations and the doses of potentially addictive drugs. CONCLUSION: The dispensation rates of potentially addictive drugs are high in the OAT population. Treatment indications, as well as requirements for prescription authority, need to be debated and made explicit. Randomized controlled trials evaluating the benefits and risks of such co-prescription are required.
format Online
Article
Text
id pubmed-7183604
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-71836042020-04-29 Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017 Vold, Jørn Henrik Skurtveit, Svetlana Aas, Christer Chalabianloo, Fatemeh Kloster, Pia Synnøve Johansson, Kjell Arne Fadnes, Lars Thore BMC Health Serv Res Research Article BACKGROUND: Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients on opioid agonist therapy (OAT) are common and have pros and cons. The objectives of the current study are to define the dispensation rates of these potentially addictive drugs, and whether the number and the mean daily doses of dispensed OAT opioids and discontinuing OAT, are associated with being dispensed benzodiazepines, z-hypnotics and gabapentinoids among patients on OAT in Norway in the period 2013 to 2017. METHODS: Information about all dispensed opioids, benzodiazepines, z-hypnotics and gabapentinoids were recorded from the Norwegian Prescription Database (NorPD). A total of 10,371 OAT patients were included in the study period. The dispensation rates were defined as the number of patients who were dispensed at least one of the potentially addictive drugs divided among the number of patients who have dispensed an OAT opioid per calendar year. Mean daily doses were calculated, and for benzodiazepines and z-hypnotics, stated in diazepam equivalents. The association between dispensed potentially addictive drugs, and the number and the type of dispensed OAT opioids were calculated by using logistic regression models. RESULTS: Half of the OAT patients received at least one dispensation of a benzodiazepine or z-hypnotic, and 11% were dispensed at least a gabapentinoid in 2017. For dispensed benzodiazepines or z-hypnotics, the mean daily dose was reduced from 21 mg (95% confidence interval (CI): 20–23) diazepam equivalents in 2013 to 17 mg (95% CI: 16–17) in 2017. The mean daily dose of pregabalin increased from 365 mg (95% CI: 309–421) in 2013 to 386 mg (95% CI: 349–423) in 2017. Being dispensed a gabapentinoid (adjusted odds ratio (aOR) = 2.5, 95% CI: 2.1–3.0) or a non-OAT opioid (aOR = 3.0, 95% CI: 2.6–3.5) was associated with being dispensed a benzodiazepine or z-hypnotic. Discontinuing OAT did not affect the number of dispensations and the doses of potentially addictive drugs. CONCLUSION: The dispensation rates of potentially addictive drugs are high in the OAT population. Treatment indications, as well as requirements for prescription authority, need to be debated and made explicit. Randomized controlled trials evaluating the benefits and risks of such co-prescription are required. BioMed Central 2020-04-25 /pmc/articles/PMC7183604/ /pubmed/32334602 http://dx.doi.org/10.1186/s12913-020-05195-5 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Vold, Jørn Henrik
Skurtveit, Svetlana
Aas, Christer
Chalabianloo, Fatemeh
Kloster, Pia Synnøve
Johansson, Kjell Arne
Fadnes, Lars Thore
Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017
title Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017
title_full Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017
title_fullStr Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017
title_full_unstemmed Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017
title_short Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in Norway from 2013 to 2017
title_sort dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; a prospective cohort study in norway from 2013 to 2017
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183604/
https://www.ncbi.nlm.nih.gov/pubmed/32334602
http://dx.doi.org/10.1186/s12913-020-05195-5
work_keys_str_mv AT voldjørnhenrik dispensationsofbenzodiazepineszhypnoticsandgabapentinoidstopatientsreceivingopioidagonisttherapyaprospectivecohortstudyinnorwayfrom2013to2017
AT skurtveitsvetlana dispensationsofbenzodiazepineszhypnoticsandgabapentinoidstopatientsreceivingopioidagonisttherapyaprospectivecohortstudyinnorwayfrom2013to2017
AT aaschrister dispensationsofbenzodiazepineszhypnoticsandgabapentinoidstopatientsreceivingopioidagonisttherapyaprospectivecohortstudyinnorwayfrom2013to2017
AT chalabianloofatemeh dispensationsofbenzodiazepineszhypnoticsandgabapentinoidstopatientsreceivingopioidagonisttherapyaprospectivecohortstudyinnorwayfrom2013to2017
AT klosterpiasynnøve dispensationsofbenzodiazepineszhypnoticsandgabapentinoidstopatientsreceivingopioidagonisttherapyaprospectivecohortstudyinnorwayfrom2013to2017
AT johanssonkjellarne dispensationsofbenzodiazepineszhypnoticsandgabapentinoidstopatientsreceivingopioidagonisttherapyaprospectivecohortstudyinnorwayfrom2013to2017
AT fadneslarsthore dispensationsofbenzodiazepineszhypnoticsandgabapentinoidstopatientsreceivingopioidagonisttherapyaprospectivecohortstudyinnorwayfrom2013to2017